›
›
›
›
Medtech lead generation playbook 2026: medical devices
Medtech lead generation playbook 2026: medical devices
Medtech lead generation playbook 2026: medical devices
Medtech lead generation playbook 2026: medical devices
Medtech lead generation playbook 2026: medical devices
Medtech lead generation playbook 2026: medical devices
Author
Aljaz Peklaj
Medtech and medical device lead generation playbook 2026
TL;DR
Medical devices are bought by groups, not people: health systems, GPOs, value analysis committees, public tenders, clinicians, biomedical engineering and distributors. Component suppliers sell to OEM quality and sourcing teams instead.
The market is large and concentrated. MedTech Europe puts the US at 47.6% and Europe at 25.6% of the world medical device market in 2025, with Europe growing just 1.8%.
Marketing is regulated. EU MDR Article 7 bans misleading claims, the FDA treats most advertising as labeling, and the MedTech Europe and AdvaMed codes govern how you deal with healthcare professionals.
The motion that works is a named account list worked through LinkedIn, outbound to supply chain and clinical leads, KOL and education programmes, distributors and a few events such as MEDICA (16 to 19 November 2026).
Medtech lead generation means opening conversations with the hospitals, health systems, purchasing groups, distributors and manufacturers that buy medical devices and the parts inside them. It is slow, evidence-driven and regulated, so the work is mapping the buying group, matching evidence to each member and keeping every message inside your cleared claims. This playbook covers who buys, the 2026 market numbers, how buying cycles work, the rules that shape marketing, the events and channels to use and how to write messages that pass review.
Who buys medical devices
A device company rarely sells to one person. A new surgical product can need a clinical champion, a value analysis committee, a supply chain lead, a contract through a group purchasing organisation (GPO) and sign-off from biomedical engineering. A component supplier sells to an entirely different group: the OEM's sourcing and quality teams. Start by naming every buyer group you need, because the list decides your message, your evidence and your channels.
Figure: medtech buyer groups, what each decides and the evidence it asks for. GROU segmentation, 15 October 2026.
Hospitals and health systems. In the US most hospitals sit inside systems. The American Hospital Association's Fast Facts 2026 counts 6,100 US hospitals, and 3,567 of the 5,121 community hospitals belong to a health system. System-level standardisation means one decision can cover many sites.
GPOs. The Healthcare Supply Chain Association, the trade body for GPOs, says more than 100 GPOs serve US providers and more than 7,000 hospitals use one. A GPO contract gives you access and pricing tiers, not volume: the hospital still has to choose you.
Value analysis committees. These decide whether a new product gets on the shelf. At the University of Toledo's surgical value analysis committee, voting members include surgical and cardiovascular directors, finance, infection prevention, supply chain, radiology and sterile processing. Requests need clinical justification, estimated cost, expected volume and workflow impact. The clinical champion presents, not the vendor, and "approval of trial does not constitute approval for purchase."
Public procurement. In the EU, public hospitals buy through tenders. Article 67 of Directive 2014/24/EU requires contracts to be awarded on the most economically advantageous tender, which can weigh life-cycle cost and quality, not only price. Tenders are published on TED, so they are a trackable signal.
Clinicians and key opinion leaders (KOLs). They drive preference and adoption, and they trust peer-reviewed data and hands-on training over marketing.
Biomedical and clinical engineering. They own integration, servicing and device safety, and increasingly cybersecurity for connected devices.
Distributors. In many markets they own the hospital relationship. Under the EU MDR, distributors must check CE marking, the declaration of conformity and labeling before they make a device available (Article 14), so they will ask for your documentation early.
OEM buyers. If you sell components, materials or contract manufacturing, your buyer is the device maker's sourcing, engineering and quality team, and supplier qualification is the gate.
The medtech market in numbers
The device market is big, concentrated in two regions and slowing in Europe. The figures worth knowing before you build a list:
Europe. MedTech Europe's Facts & Figures 2026 estimates the European medical technology market at roughly €173 billion in 2025. Growth slowed to 1.8% in 2025, against an average of 5.6% a year over the past decade. Europe has more than 36,000 medtech companies, around 90% of them SMEs, and the report records the first-ever fall in company numbers.
World share. On manufacturer prices, the US holds 47.6% of the world medical device market and Europe 25.6%, down from 26.4% a year earlier, per the same report.
Global size. Fortune Business Insights values the global market at $572.31 billion in 2025 and forecasts $1,032.66 billion by 2034, a 6.90% annual growth rate from 2026. Market research firms define the market differently, so do not mix their totals with MedTech Europe's.
US activity. The FDA's CDRH Annual Report 2025 says the agency received 21,780 medical device submissions in 2025, oversaw 25,530 registered device manufacturing firms and authorised 124 novel devices. It has authorised more than 1,300 AI-enabled devices to date.
US industry. AdvaMed counts more than 6,500 US medtech firms, over 80% of them with fewer than 50 employees. Its figures come from a 2021 statistical update, so treat them as dated.
Figure: share of the world medical device market in 2025 by region, MedTech Europe Facts & Figures 2026.
What this means for lead generation: buyers in Europe are under budget pressure, and MedTech Europe notes purchasing priorities are shifting toward supply security, long-term value and sustainability. A pitch built only on price lands badly. A pitch built on outcomes, total cost and supply resilience fits how buyers now score bids.
Buying cycles and evidence requirements
We do not quote a typical medtech sales cycle, because we know of no credible public benchmark for one. What is consistent is the order and the evidence each step needs:
A clinical or operational problem owner. A department lead, a surgeon or a supply chain director who wants a change.
Evidence review. Clinical data, regulatory status (CE marking under the MDR, FDA clearance or approval), and for connected devices, security documentation.
Value analysis or tender. A committee or tender panel weighs cost, outcomes, workflow, infection control and supply. Trials are common, and a trial is not a purchase.
Contracting. GPO agreements, local contracts or tender awards, then supplier onboarding.
Two things lengthen the cycle. Capital equipment goes through annual budget rounds, so timing matters. And new products need a champion inside the hospital, because vendors usually cannot present to the committee themselves.
Regulatory timelines shape demand too. Devices certified under the old EU directives can stay on the market until 31 December 2027 for class III and most class IIb implantables and until 31 December 2028 for other classes, under Regulation (EU) 2023/607. Manufacturers moving to MDR certificates are buying regulatory, clinical evidence and testing services now. The Commission also proposed a revision of the MDR and IVDR on 16 December 2025, as Covington summarised; it still needs Parliament and Council approval.
Rules that shape medtech marketing
Medtech marketing has more rules than most B2B categories. Get these wrong and the campaign is not just weak, it is a compliance issue.
EU MDR claims. Article 7 of the Medical Devices Regulation applies to labeling, instructions for use, making available, putting into service and advertising. It prohibits text, names, pictures or signs that may mislead the user or patient about the device's intended purpose, safety and performance, including "suggesting uses for the device other than those stated to form part of the intended purpose for which the conformity assessment was carried out."
US FDA. The FDA's device labeling guidance says "Most, if not all advertising, is labeling." Intended use is judged broadly: 21 CFR 801.4 says objective intent "may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives." A rep's email or LinkedIn message counts.
Codes for interactions with healthcare professionals.
Europe. The MedTech Europe Code of Ethical Business Practice phased out direct sponsorship of HCPs attending third-party organised conferences by 1 January 2018. Support now goes through educational grants to healthcare organisations, disclosed on the Transparent MedTech platform, and third-party events are reviewed through the Conference Vetting System.
US. The AdvaMed Code of Ethics covers consulting arrangements, training, education and other communications with healthcare professionals. Its latest updates took effect on 1 November 2025.
US Sunshine Act. Device and drug makers report payments and transfers of value to covered recipients through Open Payments. Program Year 2025 data covers 17.07 million records totalling $14.67 billion, and CMS publishes each year's data by 30 June.
Data protection. Clinicians and buyers are named individuals, so GDPR applies to your prospect lists in Europe. Our GDPR cold email playbook covers the lawful basis and opt-out rules.
Together, these rules come down to 15 checks to run on every ad, email and event invite before it goes live.
Figure: 15 checks to run on every medtech campaign, built from EU MDR Article 7, 21 CFR 801.4, the MedTech Europe Code and CMS Open Payments.
Channels that reach medtech buyers
No single channel covers a buying group this wide. Run four channels against one named account list so each member hears from you where they spend time.
Figure: four channels for medtech lead generation and what each does. Sources: LinkedIn, CMS, MedTech Europe.
LinkedIn. LinkedIn's ad targeting covers company, job title, industry and seniority, plus contact and account lists and website retargeting. LinkedIn's industry taxonomy includes Hospitals and Health Care and Manufacturing > Medical Equipment Manufacturing, which is useful for component suppliers (our manufacturing lead generation page covers that side). Upload your account list, then layer roles such as supply chain, value analysis, perioperative leads and biomedical engineering. Use Sales Navigator alerts to track job changes at target accounts. Our LinkedIn ads playbook covers setup.
ABM and outbound to procurement and clinical leads. Medtech account lists are short enough to research one by one. Build the list in Apollo or ZoomInfo, enrich it in Clay, and reach three to five people per account across supply chain, clinical and engineering. HeyReach helps when you run LinkedIn outreach from several sender profiles. Lead with evidence and a specific operational problem, not a product tour. Our guide to ABM tiers shows how to split effort by account value, and ABM for manufacturers covers the OEM side.
KOLs and clinical education. Clinicians adopt what peers they trust use and teach. Work with KOLs on education, training and evidence, under written contracts at fair market value, and remember that in the US every payment ends up in a public database. Keep KOL programmes run by medical or clinical teams, with marketing supporting, not leading.
Distributors. In many European, Middle Eastern and Asian markets the distributor owns the hospital relationship and the tender process. Recruit distributors with the same rigour as customers, then give them sales-ready material: claims-approved decks, evidence summaries and tender documentation.
Signals worth tracking. Tender notices on TED, new FDA clearances in the 510(k) database (a cleared device often means new component, testing or distribution needs), hospital system mergers, new service line openings and leadership changes in supply chain. Our guide to signal-based lead generation shows how to turn these into a daily feed.
The medtech event calendar
Events are where hospital buyers, distributors and OEMs still meet in person. These are the dates the organisers had published when we checked:
Figure: medtech events from November 2026 to October 2027 with dates published by the organisers, checked 15 October 2026.
MEDICA 2026, 16 to 19 November 2026, Dusseldorf. The MEDICA site lists 4,821 exhibitors and 78,000 visitors, without tying the figures to an edition.
COMPAMED 2026, 16 to 19 November 2026, Dusseldorf, alongside MEDICA. COMPAMED is the marketplace for the medical supplier industry, which makes it the event for component and contract manufacturing sales.
WHX Dubai 2027, 25 to 28 January 2027. World Health Expo is the evolution of Arab Health, split across Dubai Exhibition Centre and Dubai World Trade Centre.
MD&M West 2027, 9 to 11 February 2027, Anaheim Convention Center. The MD&M West site lists 13,800+ verified attendees and 1,700+ exhibitors.
WHX Miami 2027, 16 to 18 June 2027, Miami Beach Convention Center. WHX Miami is the former FIME.
The MedTech Conference, AdvaMed's annual event. The 2026 edition ran 18 to 21 October in Boston; 2027 dates were not published when we checked.
Pick events by buyer: MEDICA and WHX for hospital buyers and distributors, COMPAMED and MD&M West for OEM and supplier sales, The MedTech Conference for industry partnerships. Our list of the best B2B events covers how to book meetings before the event.
Compliant messaging that still lands
Compliance does not have to make your messaging bland. It forces it to be specific, which is what clinical and supply chain buyers want anyway.
Lead with the problem, not the device. Infection risk, theatre time, staff time, readmissions, supply disruption. Ask about the problem before you mention a product.
Use your cleared claims verbatim. Build a claims library from your intended purpose and approved labeling, and write every ad, email and sequence from it.
Match evidence to the reader. Clinicians want study design and outcomes. Supply chain wants cost per procedure and supply terms. Biomedical engineering wants specs, service and security.
Put a reviewer in the loop for one-to-one messages. Ads go through regulatory review. Outbound sequences and LinkedIn messages need the same review, because a rep's written statement can show intended use.
Separate commercial from clinical. Invitations to education events, product training and KOL work follow the codes. Keep them out of sales sequences.
If you also sell to pharma or digital health buyers, our pharma lead generation and healthtech lead generation playbooks cover the differences.
FAQ
How do medical device companies generate leads?
They build a named account list of health systems, hospitals, distributors or OEMs, map the buying group in each, and reach those people through LinkedIn, outbound, clinical education and a few events. Leads come from evidence-led conversations with supply chain and clinical owners, not from broad campaigns.
Who makes purchasing decisions for medical devices in hospitals?
Usually a group. A clinical champion requests the product, a value analysis committee with clinical, finance, infection prevention and supply chain members reviews it, and procurement or a GPO contract sets the terms. Biomedical engineering signs off on integration and servicing.
What is a value analysis committee?
A hospital committee that reviews new product requests against clinical evidence, cost, safety and workflow. Vendors usually cannot present directly; a clinical champion brings the request, and a trial approval is not a purchase approval.
Can medical device companies advertise on LinkedIn?
Yes. LinkedIn lets you target by company, job title, industry and seniority, including Hospitals and Health Care and Medical Equipment Manufacturing. Every ad must stay within your cleared or certified claims under the EU MDR and FDA rules.
What are the EU MDR rules on medical device advertising?
Article 7 of the MDR bans misleading text, names or images in labeling and advertising, including claiming functions the device does not have, hiding risks or suggesting uses beyond the intended purpose assessed for conformity.
When is MEDICA 2026?
MEDICA 2026 runs from 16 to 19 November 2026 in Dusseldorf, with COMPAMED alongside it on the same dates.
Bottom line
Medtech lead generation rewards precision. Map the whole buying group, from supply chain and value analysis to clinicians, biomedical engineering and distributors. Match your evidence to each of them, keep every message inside your cleared claims, and work a short account list through LinkedIn, outbound, KOL education and a few well-chosen events. The European market is growing slowly and buyers are scoring on value and supply security, so the vendors who show outcomes and total cost will get the meetings.
If you want a medtech pipeline built on named accounts and compliant outreach, book a call with GROU.
About this guide
We are GROU, a B2B pipeline agency that runs lead generation, outbound and LinkedIn content for B2B companies. The market data, rules and event dates in this guide come from MedTech Europe, the FDA, AdvaMed, the AHA, EU law, CMS and the event organisers, checked on 15 October 2026.
Some links in this article are affiliate. We may earn a small commission at no extra cost to you.
Medtech and medical device lead generation playbook 2026
TL;DR
Medical devices are bought by groups, not people: health systems, GPOs, value analysis committees, public tenders, clinicians, biomedical engineering and distributors. Component suppliers sell to OEM quality and sourcing teams instead.
The market is large and concentrated. MedTech Europe puts the US at 47.6% and Europe at 25.6% of the world medical device market in 2025, with Europe growing just 1.8%.
Marketing is regulated. EU MDR Article 7 bans misleading claims, the FDA treats most advertising as labeling, and the MedTech Europe and AdvaMed codes govern how you deal with healthcare professionals.
The motion that works is a named account list worked through LinkedIn, outbound to supply chain and clinical leads, KOL and education programmes, distributors and a few events such as MEDICA (16 to 19 November 2026).
Medtech lead generation means opening conversations with the hospitals, health systems, purchasing groups, distributors and manufacturers that buy medical devices and the parts inside them. It is slow, evidence-driven and regulated, so the work is mapping the buying group, matching evidence to each member and keeping every message inside your cleared claims. This playbook covers who buys, the 2026 market numbers, how buying cycles work, the rules that shape marketing, the events and channels to use and how to write messages that pass review.
Who buys medical devices
A device company rarely sells to one person. A new surgical product can need a clinical champion, a value analysis committee, a supply chain lead, a contract through a group purchasing organisation (GPO) and sign-off from biomedical engineering. A component supplier sells to an entirely different group: the OEM's sourcing and quality teams. Start by naming every buyer group you need, because the list decides your message, your evidence and your channels.
Figure: medtech buyer groups, what each decides and the evidence it asks for. GROU segmentation, 15 October 2026.
Hospitals and health systems. In the US most hospitals sit inside systems. The American Hospital Association's Fast Facts 2026 counts 6,100 US hospitals, and 3,567 of the 5,121 community hospitals belong to a health system. System-level standardisation means one decision can cover many sites.
GPOs. The Healthcare Supply Chain Association, the trade body for GPOs, says more than 100 GPOs serve US providers and more than 7,000 hospitals use one. A GPO contract gives you access and pricing tiers, not volume: the hospital still has to choose you.
Value analysis committees. These decide whether a new product gets on the shelf. At the University of Toledo's surgical value analysis committee, voting members include surgical and cardiovascular directors, finance, infection prevention, supply chain, radiology and sterile processing. Requests need clinical justification, estimated cost, expected volume and workflow impact. The clinical champion presents, not the vendor, and "approval of trial does not constitute approval for purchase."
Public procurement. In the EU, public hospitals buy through tenders. Article 67 of Directive 2014/24/EU requires contracts to be awarded on the most economically advantageous tender, which can weigh life-cycle cost and quality, not only price. Tenders are published on TED, so they are a trackable signal.
Clinicians and key opinion leaders (KOLs). They drive preference and adoption, and they trust peer-reviewed data and hands-on training over marketing.
Biomedical and clinical engineering. They own integration, servicing and device safety, and increasingly cybersecurity for connected devices.
Distributors. In many markets they own the hospital relationship. Under the EU MDR, distributors must check CE marking, the declaration of conformity and labeling before they make a device available (Article 14), so they will ask for your documentation early.
OEM buyers. If you sell components, materials or contract manufacturing, your buyer is the device maker's sourcing, engineering and quality team, and supplier qualification is the gate.
The medtech market in numbers
The device market is big, concentrated in two regions and slowing in Europe. The figures worth knowing before you build a list:
Europe. MedTech Europe's Facts & Figures 2026 estimates the European medical technology market at roughly €173 billion in 2025. Growth slowed to 1.8% in 2025, against an average of 5.6% a year over the past decade. Europe has more than 36,000 medtech companies, around 90% of them SMEs, and the report records the first-ever fall in company numbers.
World share. On manufacturer prices, the US holds 47.6% of the world medical device market and Europe 25.6%, down from 26.4% a year earlier, per the same report.
Global size. Fortune Business Insights values the global market at $572.31 billion in 2025 and forecasts $1,032.66 billion by 2034, a 6.90% annual growth rate from 2026. Market research firms define the market differently, so do not mix their totals with MedTech Europe's.
US activity. The FDA's CDRH Annual Report 2025 says the agency received 21,780 medical device submissions in 2025, oversaw 25,530 registered device manufacturing firms and authorised 124 novel devices. It has authorised more than 1,300 AI-enabled devices to date.
US industry. AdvaMed counts more than 6,500 US medtech firms, over 80% of them with fewer than 50 employees. Its figures come from a 2021 statistical update, so treat them as dated.
Figure: share of the world medical device market in 2025 by region, MedTech Europe Facts & Figures 2026.
What this means for lead generation: buyers in Europe are under budget pressure, and MedTech Europe notes purchasing priorities are shifting toward supply security, long-term value and sustainability. A pitch built only on price lands badly. A pitch built on outcomes, total cost and supply resilience fits how buyers now score bids.
Buying cycles and evidence requirements
We do not quote a typical medtech sales cycle, because we know of no credible public benchmark for one. What is consistent is the order and the evidence each step needs:
A clinical or operational problem owner. A department lead, a surgeon or a supply chain director who wants a change.
Evidence review. Clinical data, regulatory status (CE marking under the MDR, FDA clearance or approval), and for connected devices, security documentation.
Value analysis or tender. A committee or tender panel weighs cost, outcomes, workflow, infection control and supply. Trials are common, and a trial is not a purchase.
Contracting. GPO agreements, local contracts or tender awards, then supplier onboarding.
Two things lengthen the cycle. Capital equipment goes through annual budget rounds, so timing matters. And new products need a champion inside the hospital, because vendors usually cannot present to the committee themselves.
Regulatory timelines shape demand too. Devices certified under the old EU directives can stay on the market until 31 December 2027 for class III and most class IIb implantables and until 31 December 2028 for other classes, under Regulation (EU) 2023/607. Manufacturers moving to MDR certificates are buying regulatory, clinical evidence and testing services now. The Commission also proposed a revision of the MDR and IVDR on 16 December 2025, as Covington summarised; it still needs Parliament and Council approval.
Rules that shape medtech marketing
Medtech marketing has more rules than most B2B categories. Get these wrong and the campaign is not just weak, it is a compliance issue.
EU MDR claims. Article 7 of the Medical Devices Regulation applies to labeling, instructions for use, making available, putting into service and advertising. It prohibits text, names, pictures or signs that may mislead the user or patient about the device's intended purpose, safety and performance, including "suggesting uses for the device other than those stated to form part of the intended purpose for which the conformity assessment was carried out."
US FDA. The FDA's device labeling guidance says "Most, if not all advertising, is labeling." Intended use is judged broadly: 21 CFR 801.4 says objective intent "may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives." A rep's email or LinkedIn message counts.
Codes for interactions with healthcare professionals.
Europe. The MedTech Europe Code of Ethical Business Practice phased out direct sponsorship of HCPs attending third-party organised conferences by 1 January 2018. Support now goes through educational grants to healthcare organisations, disclosed on the Transparent MedTech platform, and third-party events are reviewed through the Conference Vetting System.
US. The AdvaMed Code of Ethics covers consulting arrangements, training, education and other communications with healthcare professionals. Its latest updates took effect on 1 November 2025.
US Sunshine Act. Device and drug makers report payments and transfers of value to covered recipients through Open Payments. Program Year 2025 data covers 17.07 million records totalling $14.67 billion, and CMS publishes each year's data by 30 June.
Data protection. Clinicians and buyers are named individuals, so GDPR applies to your prospect lists in Europe. Our GDPR cold email playbook covers the lawful basis and opt-out rules.
Together, these rules come down to 15 checks to run on every ad, email and event invite before it goes live.
Figure: 15 checks to run on every medtech campaign, built from EU MDR Article 7, 21 CFR 801.4, the MedTech Europe Code and CMS Open Payments.
Channels that reach medtech buyers
No single channel covers a buying group this wide. Run four channels against one named account list so each member hears from you where they spend time.
Figure: four channels for medtech lead generation and what each does. Sources: LinkedIn, CMS, MedTech Europe.
LinkedIn. LinkedIn's ad targeting covers company, job title, industry and seniority, plus contact and account lists and website retargeting. LinkedIn's industry taxonomy includes Hospitals and Health Care and Manufacturing > Medical Equipment Manufacturing, which is useful for component suppliers (our manufacturing lead generation page covers that side). Upload your account list, then layer roles such as supply chain, value analysis, perioperative leads and biomedical engineering. Use Sales Navigator alerts to track job changes at target accounts. Our LinkedIn ads playbook covers setup.
ABM and outbound to procurement and clinical leads. Medtech account lists are short enough to research one by one. Build the list in Apollo or ZoomInfo, enrich it in Clay, and reach three to five people per account across supply chain, clinical and engineering. HeyReach helps when you run LinkedIn outreach from several sender profiles. Lead with evidence and a specific operational problem, not a product tour. Our guide to ABM tiers shows how to split effort by account value, and ABM for manufacturers covers the OEM side.
KOLs and clinical education. Clinicians adopt what peers they trust use and teach. Work with KOLs on education, training and evidence, under written contracts at fair market value, and remember that in the US every payment ends up in a public database. Keep KOL programmes run by medical or clinical teams, with marketing supporting, not leading.
Distributors. In many European, Middle Eastern and Asian markets the distributor owns the hospital relationship and the tender process. Recruit distributors with the same rigour as customers, then give them sales-ready material: claims-approved decks, evidence summaries and tender documentation.
Signals worth tracking. Tender notices on TED, new FDA clearances in the 510(k) database (a cleared device often means new component, testing or distribution needs), hospital system mergers, new service line openings and leadership changes in supply chain. Our guide to signal-based lead generation shows how to turn these into a daily feed.
The medtech event calendar
Events are where hospital buyers, distributors and OEMs still meet in person. These are the dates the organisers had published when we checked:
Figure: medtech events from November 2026 to October 2027 with dates published by the organisers, checked 15 October 2026.
MEDICA 2026, 16 to 19 November 2026, Dusseldorf. The MEDICA site lists 4,821 exhibitors and 78,000 visitors, without tying the figures to an edition.
COMPAMED 2026, 16 to 19 November 2026, Dusseldorf, alongside MEDICA. COMPAMED is the marketplace for the medical supplier industry, which makes it the event for component and contract manufacturing sales.
WHX Dubai 2027, 25 to 28 January 2027. World Health Expo is the evolution of Arab Health, split across Dubai Exhibition Centre and Dubai World Trade Centre.
MD&M West 2027, 9 to 11 February 2027, Anaheim Convention Center. The MD&M West site lists 13,800+ verified attendees and 1,700+ exhibitors.
WHX Miami 2027, 16 to 18 June 2027, Miami Beach Convention Center. WHX Miami is the former FIME.
The MedTech Conference, AdvaMed's annual event. The 2026 edition ran 18 to 21 October in Boston; 2027 dates were not published when we checked.
Pick events by buyer: MEDICA and WHX for hospital buyers and distributors, COMPAMED and MD&M West for OEM and supplier sales, The MedTech Conference for industry partnerships. Our list of the best B2B events covers how to book meetings before the event.
Compliant messaging that still lands
Compliance does not have to make your messaging bland. It forces it to be specific, which is what clinical and supply chain buyers want anyway.
Lead with the problem, not the device. Infection risk, theatre time, staff time, readmissions, supply disruption. Ask about the problem before you mention a product.
Use your cleared claims verbatim. Build a claims library from your intended purpose and approved labeling, and write every ad, email and sequence from it.
Match evidence to the reader. Clinicians want study design and outcomes. Supply chain wants cost per procedure and supply terms. Biomedical engineering wants specs, service and security.
Put a reviewer in the loop for one-to-one messages. Ads go through regulatory review. Outbound sequences and LinkedIn messages need the same review, because a rep's written statement can show intended use.
Separate commercial from clinical. Invitations to education events, product training and KOL work follow the codes. Keep them out of sales sequences.
If you also sell to pharma or digital health buyers, our pharma lead generation and healthtech lead generation playbooks cover the differences.
FAQ
How do medical device companies generate leads?
They build a named account list of health systems, hospitals, distributors or OEMs, map the buying group in each, and reach those people through LinkedIn, outbound, clinical education and a few events. Leads come from evidence-led conversations with supply chain and clinical owners, not from broad campaigns.
Who makes purchasing decisions for medical devices in hospitals?
Usually a group. A clinical champion requests the product, a value analysis committee with clinical, finance, infection prevention and supply chain members reviews it, and procurement or a GPO contract sets the terms. Biomedical engineering signs off on integration and servicing.
What is a value analysis committee?
A hospital committee that reviews new product requests against clinical evidence, cost, safety and workflow. Vendors usually cannot present directly; a clinical champion brings the request, and a trial approval is not a purchase approval.
Can medical device companies advertise on LinkedIn?
Yes. LinkedIn lets you target by company, job title, industry and seniority, including Hospitals and Health Care and Medical Equipment Manufacturing. Every ad must stay within your cleared or certified claims under the EU MDR and FDA rules.
What are the EU MDR rules on medical device advertising?
Article 7 of the MDR bans misleading text, names or images in labeling and advertising, including claiming functions the device does not have, hiding risks or suggesting uses beyond the intended purpose assessed for conformity.
When is MEDICA 2026?
MEDICA 2026 runs from 16 to 19 November 2026 in Dusseldorf, with COMPAMED alongside it on the same dates.
Bottom line
Medtech lead generation rewards precision. Map the whole buying group, from supply chain and value analysis to clinicians, biomedical engineering and distributors. Match your evidence to each of them, keep every message inside your cleared claims, and work a short account list through LinkedIn, outbound, KOL education and a few well-chosen events. The European market is growing slowly and buyers are scoring on value and supply security, so the vendors who show outcomes and total cost will get the meetings.
If you want a medtech pipeline built on named accounts and compliant outreach, book a call with GROU.
About this guide
We are GROU, a B2B pipeline agency that runs lead generation, outbound and LinkedIn content for B2B companies. The market data, rules and event dates in this guide come from MedTech Europe, the FDA, AdvaMed, the AHA, EU law, CMS and the event organisers, checked on 15 October 2026.
Some links in this article are affiliate. We may earn a small commission at no extra cost to you.
Medtech and medical device lead generation playbook 2026
TL;DR
Medical devices are bought by groups, not people: health systems, GPOs, value analysis committees, public tenders, clinicians, biomedical engineering and distributors. Component suppliers sell to OEM quality and sourcing teams instead.
The market is large and concentrated. MedTech Europe puts the US at 47.6% and Europe at 25.6% of the world medical device market in 2025, with Europe growing just 1.8%.
Marketing is regulated. EU MDR Article 7 bans misleading claims, the FDA treats most advertising as labeling, and the MedTech Europe and AdvaMed codes govern how you deal with healthcare professionals.
The motion that works is a named account list worked through LinkedIn, outbound to supply chain and clinical leads, KOL and education programmes, distributors and a few events such as MEDICA (16 to 19 November 2026).
Medtech lead generation means opening conversations with the hospitals, health systems, purchasing groups, distributors and manufacturers that buy medical devices and the parts inside them. It is slow, evidence-driven and regulated, so the work is mapping the buying group, matching evidence to each member and keeping every message inside your cleared claims. This playbook covers who buys, the 2026 market numbers, how buying cycles work, the rules that shape marketing, the events and channels to use and how to write messages that pass review.
Who buys medical devices
A device company rarely sells to one person. A new surgical product can need a clinical champion, a value analysis committee, a supply chain lead, a contract through a group purchasing organisation (GPO) and sign-off from biomedical engineering. A component supplier sells to an entirely different group: the OEM's sourcing and quality teams. Start by naming every buyer group you need, because the list decides your message, your evidence and your channels.
Figure: medtech buyer groups, what each decides and the evidence it asks for. GROU segmentation, 15 October 2026.
Hospitals and health systems. In the US most hospitals sit inside systems. The American Hospital Association's Fast Facts 2026 counts 6,100 US hospitals, and 3,567 of the 5,121 community hospitals belong to a health system. System-level standardisation means one decision can cover many sites.
GPOs. The Healthcare Supply Chain Association, the trade body for GPOs, says more than 100 GPOs serve US providers and more than 7,000 hospitals use one. A GPO contract gives you access and pricing tiers, not volume: the hospital still has to choose you.
Value analysis committees. These decide whether a new product gets on the shelf. At the University of Toledo's surgical value analysis committee, voting members include surgical and cardiovascular directors, finance, infection prevention, supply chain, radiology and sterile processing. Requests need clinical justification, estimated cost, expected volume and workflow impact. The clinical champion presents, not the vendor, and "approval of trial does not constitute approval for purchase."
Public procurement. In the EU, public hospitals buy through tenders. Article 67 of Directive 2014/24/EU requires contracts to be awarded on the most economically advantageous tender, which can weigh life-cycle cost and quality, not only price. Tenders are published on TED, so they are a trackable signal.
Clinicians and key opinion leaders (KOLs). They drive preference and adoption, and they trust peer-reviewed data and hands-on training over marketing.
Biomedical and clinical engineering. They own integration, servicing and device safety, and increasingly cybersecurity for connected devices.
Distributors. In many markets they own the hospital relationship. Under the EU MDR, distributors must check CE marking, the declaration of conformity and labeling before they make a device available (Article 14), so they will ask for your documentation early.
OEM buyers. If you sell components, materials or contract manufacturing, your buyer is the device maker's sourcing, engineering and quality team, and supplier qualification is the gate.
The medtech market in numbers
The device market is big, concentrated in two regions and slowing in Europe. The figures worth knowing before you build a list:
Europe. MedTech Europe's Facts & Figures 2026 estimates the European medical technology market at roughly €173 billion in 2025. Growth slowed to 1.8% in 2025, against an average of 5.6% a year over the past decade. Europe has more than 36,000 medtech companies, around 90% of them SMEs, and the report records the first-ever fall in company numbers.
World share. On manufacturer prices, the US holds 47.6% of the world medical device market and Europe 25.6%, down from 26.4% a year earlier, per the same report.
Global size. Fortune Business Insights values the global market at $572.31 billion in 2025 and forecasts $1,032.66 billion by 2034, a 6.90% annual growth rate from 2026. Market research firms define the market differently, so do not mix their totals with MedTech Europe's.
US activity. The FDA's CDRH Annual Report 2025 says the agency received 21,780 medical device submissions in 2025, oversaw 25,530 registered device manufacturing firms and authorised 124 novel devices. It has authorised more than 1,300 AI-enabled devices to date.
US industry. AdvaMed counts more than 6,500 US medtech firms, over 80% of them with fewer than 50 employees. Its figures come from a 2021 statistical update, so treat them as dated.
Figure: share of the world medical device market in 2025 by region, MedTech Europe Facts & Figures 2026.
What this means for lead generation: buyers in Europe are under budget pressure, and MedTech Europe notes purchasing priorities are shifting toward supply security, long-term value and sustainability. A pitch built only on price lands badly. A pitch built on outcomes, total cost and supply resilience fits how buyers now score bids.
Buying cycles and evidence requirements
We do not quote a typical medtech sales cycle, because we know of no credible public benchmark for one. What is consistent is the order and the evidence each step needs:
A clinical or operational problem owner. A department lead, a surgeon or a supply chain director who wants a change.
Evidence review. Clinical data, regulatory status (CE marking under the MDR, FDA clearance or approval), and for connected devices, security documentation.
Value analysis or tender. A committee or tender panel weighs cost, outcomes, workflow, infection control and supply. Trials are common, and a trial is not a purchase.
Contracting. GPO agreements, local contracts or tender awards, then supplier onboarding.
Two things lengthen the cycle. Capital equipment goes through annual budget rounds, so timing matters. And new products need a champion inside the hospital, because vendors usually cannot present to the committee themselves.
Regulatory timelines shape demand too. Devices certified under the old EU directives can stay on the market until 31 December 2027 for class III and most class IIb implantables and until 31 December 2028 for other classes, under Regulation (EU) 2023/607. Manufacturers moving to MDR certificates are buying regulatory, clinical evidence and testing services now. The Commission also proposed a revision of the MDR and IVDR on 16 December 2025, as Covington summarised; it still needs Parliament and Council approval.
Rules that shape medtech marketing
Medtech marketing has more rules than most B2B categories. Get these wrong and the campaign is not just weak, it is a compliance issue.
EU MDR claims. Article 7 of the Medical Devices Regulation applies to labeling, instructions for use, making available, putting into service and advertising. It prohibits text, names, pictures or signs that may mislead the user or patient about the device's intended purpose, safety and performance, including "suggesting uses for the device other than those stated to form part of the intended purpose for which the conformity assessment was carried out."
US FDA. The FDA's device labeling guidance says "Most, if not all advertising, is labeling." Intended use is judged broadly: 21 CFR 801.4 says objective intent "may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives." A rep's email or LinkedIn message counts.
Codes for interactions with healthcare professionals.
Europe. The MedTech Europe Code of Ethical Business Practice phased out direct sponsorship of HCPs attending third-party organised conferences by 1 January 2018. Support now goes through educational grants to healthcare organisations, disclosed on the Transparent MedTech platform, and third-party events are reviewed through the Conference Vetting System.
US. The AdvaMed Code of Ethics covers consulting arrangements, training, education and other communications with healthcare professionals. Its latest updates took effect on 1 November 2025.
US Sunshine Act. Device and drug makers report payments and transfers of value to covered recipients through Open Payments. Program Year 2025 data covers 17.07 million records totalling $14.67 billion, and CMS publishes each year's data by 30 June.
Data protection. Clinicians and buyers are named individuals, so GDPR applies to your prospect lists in Europe. Our GDPR cold email playbook covers the lawful basis and opt-out rules.
Together, these rules come down to 15 checks to run on every ad, email and event invite before it goes live.
Figure: 15 checks to run on every medtech campaign, built from EU MDR Article 7, 21 CFR 801.4, the MedTech Europe Code and CMS Open Payments.
Channels that reach medtech buyers
No single channel covers a buying group this wide. Run four channels against one named account list so each member hears from you where they spend time.
Figure: four channels for medtech lead generation and what each does. Sources: LinkedIn, CMS, MedTech Europe.
LinkedIn. LinkedIn's ad targeting covers company, job title, industry and seniority, plus contact and account lists and website retargeting. LinkedIn's industry taxonomy includes Hospitals and Health Care and Manufacturing > Medical Equipment Manufacturing, which is useful for component suppliers (our manufacturing lead generation page covers that side). Upload your account list, then layer roles such as supply chain, value analysis, perioperative leads and biomedical engineering. Use Sales Navigator alerts to track job changes at target accounts. Our LinkedIn ads playbook covers setup.
ABM and outbound to procurement and clinical leads. Medtech account lists are short enough to research one by one. Build the list in Apollo or ZoomInfo, enrich it in Clay, and reach three to five people per account across supply chain, clinical and engineering. HeyReach helps when you run LinkedIn outreach from several sender profiles. Lead with evidence and a specific operational problem, not a product tour. Our guide to ABM tiers shows how to split effort by account value, and ABM for manufacturers covers the OEM side.
KOLs and clinical education. Clinicians adopt what peers they trust use and teach. Work with KOLs on education, training and evidence, under written contracts at fair market value, and remember that in the US every payment ends up in a public database. Keep KOL programmes run by medical or clinical teams, with marketing supporting, not leading.
Distributors. In many European, Middle Eastern and Asian markets the distributor owns the hospital relationship and the tender process. Recruit distributors with the same rigour as customers, then give them sales-ready material: claims-approved decks, evidence summaries and tender documentation.
Signals worth tracking. Tender notices on TED, new FDA clearances in the 510(k) database (a cleared device often means new component, testing or distribution needs), hospital system mergers, new service line openings and leadership changes in supply chain. Our guide to signal-based lead generation shows how to turn these into a daily feed.
The medtech event calendar
Events are where hospital buyers, distributors and OEMs still meet in person. These are the dates the organisers had published when we checked:
Figure: medtech events from November 2026 to October 2027 with dates published by the organisers, checked 15 October 2026.
MEDICA 2026, 16 to 19 November 2026, Dusseldorf. The MEDICA site lists 4,821 exhibitors and 78,000 visitors, without tying the figures to an edition.
COMPAMED 2026, 16 to 19 November 2026, Dusseldorf, alongside MEDICA. COMPAMED is the marketplace for the medical supplier industry, which makes it the event for component and contract manufacturing sales.
WHX Dubai 2027, 25 to 28 January 2027. World Health Expo is the evolution of Arab Health, split across Dubai Exhibition Centre and Dubai World Trade Centre.
MD&M West 2027, 9 to 11 February 2027, Anaheim Convention Center. The MD&M West site lists 13,800+ verified attendees and 1,700+ exhibitors.
WHX Miami 2027, 16 to 18 June 2027, Miami Beach Convention Center. WHX Miami is the former FIME.
The MedTech Conference, AdvaMed's annual event. The 2026 edition ran 18 to 21 October in Boston; 2027 dates were not published when we checked.
Pick events by buyer: MEDICA and WHX for hospital buyers and distributors, COMPAMED and MD&M West for OEM and supplier sales, The MedTech Conference for industry partnerships. Our list of the best B2B events covers how to book meetings before the event.
Compliant messaging that still lands
Compliance does not have to make your messaging bland. It forces it to be specific, which is what clinical and supply chain buyers want anyway.
Lead with the problem, not the device. Infection risk, theatre time, staff time, readmissions, supply disruption. Ask about the problem before you mention a product.
Use your cleared claims verbatim. Build a claims library from your intended purpose and approved labeling, and write every ad, email and sequence from it.
Match evidence to the reader. Clinicians want study design and outcomes. Supply chain wants cost per procedure and supply terms. Biomedical engineering wants specs, service and security.
Put a reviewer in the loop for one-to-one messages. Ads go through regulatory review. Outbound sequences and LinkedIn messages need the same review, because a rep's written statement can show intended use.
Separate commercial from clinical. Invitations to education events, product training and KOL work follow the codes. Keep them out of sales sequences.
If you also sell to pharma or digital health buyers, our pharma lead generation and healthtech lead generation playbooks cover the differences.
FAQ
How do medical device companies generate leads?
They build a named account list of health systems, hospitals, distributors or OEMs, map the buying group in each, and reach those people through LinkedIn, outbound, clinical education and a few events. Leads come from evidence-led conversations with supply chain and clinical owners, not from broad campaigns.
Who makes purchasing decisions for medical devices in hospitals?
Usually a group. A clinical champion requests the product, a value analysis committee with clinical, finance, infection prevention and supply chain members reviews it, and procurement or a GPO contract sets the terms. Biomedical engineering signs off on integration and servicing.
What is a value analysis committee?
A hospital committee that reviews new product requests against clinical evidence, cost, safety and workflow. Vendors usually cannot present directly; a clinical champion brings the request, and a trial approval is not a purchase approval.
Can medical device companies advertise on LinkedIn?
Yes. LinkedIn lets you target by company, job title, industry and seniority, including Hospitals and Health Care and Medical Equipment Manufacturing. Every ad must stay within your cleared or certified claims under the EU MDR and FDA rules.
What are the EU MDR rules on medical device advertising?
Article 7 of the MDR bans misleading text, names or images in labeling and advertising, including claiming functions the device does not have, hiding risks or suggesting uses beyond the intended purpose assessed for conformity.
When is MEDICA 2026?
MEDICA 2026 runs from 16 to 19 November 2026 in Dusseldorf, with COMPAMED alongside it on the same dates.
Bottom line
Medtech lead generation rewards precision. Map the whole buying group, from supply chain and value analysis to clinicians, biomedical engineering and distributors. Match your evidence to each of them, keep every message inside your cleared claims, and work a short account list through LinkedIn, outbound, KOL education and a few well-chosen events. The European market is growing slowly and buyers are scoring on value and supply security, so the vendors who show outcomes and total cost will get the meetings.
If you want a medtech pipeline built on named accounts and compliant outreach, book a call with GROU.
About this guide
We are GROU, a B2B pipeline agency that runs lead generation, outbound and LinkedIn content for B2B companies. The market data, rules and event dates in this guide come from MedTech Europe, the FDA, AdvaMed, the AHA, EU law, CMS and the event organisers, checked on 15 October 2026.
Some links in this article are affiliate. We may earn a small commission at no extra cost to you.
Pipeline OS Newsletter
Build qualified pipeline
Get weekly tactics to generate demand, improve lead quality, and book more meetings.
Trusted by industry leaders
Trusted by industry leaders
Trusted by industry leaders
Ready to build qualified pipeline?
Ready to build qualified pipeline?
Ready to build qualified pipeline?
Book a call to see if we're the right fit, or take the 2-minute quiz to get a clear starting point.
Book a call to see if we're the right fit, or take the 2-minute quiz to get a clear starting point.
Book a call to see if we're the right fit, or take the 2-minute quiz to get a clear starting point.
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 30 30" xmlns="http://www.w3.org/2000/svg"><path d="M 15.108 0 C 6.764 0 0 6.764 0 15.108 C 0 23.452 6.764 30.216 15.108 30.216 C 23.452 30.216 30.216 23.452 30.216 15.108 C 30.216 6.764 23.452 0 15.108 0 Z M 11.41 21.37 L 8.35 21.37 L 8.35 11.525 L 11.41 11.525 Z M 9.861 10.316 C 8.895 10.316 8.27 9.631 8.27 8.785 C 8.27 7.921 8.914 7.257 9.901 7.257 C 10.887 7.257 11.492 7.921 11.511 8.785 C 11.511 9.631 10.887 10.316 9.861 10.316 Z M 22.584 21.37 L 19.524 21.37 L 19.524 15.914 C 19.524 14.644 19.08 13.782 17.974 13.782 C 17.129 13.782 16.627 14.365 16.405 14.927 C 16.323 15.127 16.303 15.41 16.303 15.692 L 16.303 21.369 L 13.242 21.369 L 13.242 14.664 C 13.242 13.435 13.202 12.408 13.161 11.523 L 15.82 11.523 L 15.96 12.891 L 16.021 12.891 C 16.424 12.249 17.411 11.301 19.062 11.301 C 21.074 11.301 22.584 12.65 22.584 15.549 Z" fill="rgb(0, 0, 0)" height="30.21639343089746px" id="hfGbXmQR2" width="30.216393430897455px"/></svg>)
Copyright © 2026 – All Right Reserved
Copyright © 2026 – All Right Reserved
Copyright © 2026 – All Right Reserved